6 results
The primary objective is to determine the efficacy of neo-adjuvant chemotherapy to reduce tumour size below 2 cm in diameter and thus enabling conisation.
Primary Objective•*To evaluate the relative oral bioavailability of SMV, ODV, and AL-335 when administered as different concept fixed-dose combination (FDC) formulations compared to the single agents when administered together, all under fed…
To evaluate the efficacy of VX-121/TEZ/D-IVA in CF subjects who are homozygous forF508del, heterozygous for F508del and a gating (F/G) or residual function (F/RF) mutation, orhave at least 1 other TCR CFTR mutation and no F508del mutation
To evaluate the efficacy and pharmacodynamics (PD) of ELX/TEZ/IVA
To evaluate the effect of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) on glucose tolerance in CF subjects with impaired glucose tolerance (IGT) or CF related diabetes (CFRD)
The primary objective of this study is to determine the immune-activating capacity of treatment with pembrolizumab and carboplatin/paclitaxel in the neo-adjuvant setting of primary stage IV ovarian cancer as measured by the alteration in magnitude…